-
1Academic Journal
المؤلفون: D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, L. F. Shaikhelislamova, L. P. Gigolaeva, V. F. Semiglazov, Д. А. Еналдиева, П. В. Криворотько, Е. Н. Имянитов, Е. К. Жильцова, Р. В. Донских, Л. Ф. Шайхелисламова, Л. П. Гиголаева, В. Ф. Семиглазов
المساهمون: This study was supported by the Russian Science Foundation (grand No. 22-15-0266)., Работа выполнена при поддержке Российского научного фонда (гранд № 22-15-0266).
المصدر: Advances in Molecular Oncology; Том 10, № 3 (2023); 8-14 ; Успехи молекулярной онкологии; Том 10, № 3 (2023); 8-14 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2023-10-3
مصطلحات موضوعية: метастатический рак молочной железы, neoadjuvant chemotherapy, pathological complete response, triple-negative breast cancer, metastatic breast cance, неоадъювантная химиотерапия, патологический полный ответ, трижды негативный рак молочной железы
وصف الملف: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/564/308; Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старигородского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022. 252 с.; Desai N.V., Tung N.M. Medical management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast J 2020; 26(8):1506–12. DOI:10.1111/tbj.13972; Miki Y., Swensen J., Shattuck-Eidens D. et al. Strong candidate for the breast and ovarian cancer. Science 1994;266(5182):66–71. DOI:10.1126/science.7545954; Wooster R., Neuhausen S.L., Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265(5181):2088–90. DOI:10.1126/science.8091231; Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. DOI:10.1086/375033; Mavaddat N., Peock S., Frost D. et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013;105(11):812–22. DOI:10.1093/jnci/djt095; Bianchini G., Balko J.M., Mayer I.A. et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 2016;13:674–90. DOI:10.1038/nrclinonc.2016.66; Geyer F., Pareja F., Weigelt B. et al.The spectrum of triple-negative breast disease: highand lowgrade lesions. Am J Pathol 2017;187(10):2139–51. DOI:10.1016/j.ajpath.2017.03.016; Khosravi-Shahi P., Cabezón-Gutiérrez L., Custodio-Cabello S. Metastatic triple negative breast cancer: optimizing treatment options, new and emerging targeted therapies. Asia Pac J Clin Oncol 2018;14 (1):32–9. DOI:10.1111/ajco.12748; Zeichner S.B., Terawaki H., Gogineni K. A review of systemic treatment in metastatic triple-negative breast cancer. Breast Cancer (Auckl) 2016;10:25–36. DOI:10.4137/BCBCR.S32783; Tsai J., Bertoni D., Hernandez-Boussard T. et al. Lymph node ratio analysis after neoadjuvant chemotherapy is prognostic in hormone receptor-positive and triple-negative breast cancer. Ann Surg Oncol 2016;23(10):3310–6. DOI:10.1245/s10434-016-5319-8; Copson E.R., Maishman T.C., Tapper W.J. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19(2):169–80. DOI:10.1016/S1470-2045(17)30891-4; Tassone P., Tagliaferri P., Perricelli A. et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 2003;88(8):1285–91. DOI:10.1038/ sj.bjc.6600859; Burness M.L., Obeid E.I., Olopade O.I. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer 2015;15(2):e155-8. DOI:10.1016/j.clbc.2014.08.006; Liedtke C., Mazouni C., Hess K.R. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26(8):1275–81. DOI:10.1200/ JCO.2007.14.4147; Paluch-Shimon S., Friedman E., Berger R. et al. Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triplenegative breast cancer among BRCA1 mutation carriers and noncarriers. Breast Cancer Res Treat 2016;157(1):157–65. DOI:10.1007/s10549-016-3800-5; Weaver B.A. How taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014;25(18):2677–81. DOI:10.1091/mbc.E14-04-0916; Gluz O., Liedtke C., Gottschalk N. et al. Triple-negative breast cancer – current status and future directions. Ann Oncol 2009;20(12):1913–27. DOI:10.1093/annonc/mdp492; Arun B., Bayraktar S., Liu D.D. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol 2011;29(28):3739–46. DOI:10.1200/JCO.2011.35.2682; Bignon L., Fricker J., Nogues C. et al. Efficacy of anthracycline/ taxanebased neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. Breast J 2018;24(3): 269–77. DOI:10.1111/tbj.12887; Desai N.V., Tung N.M. Medical management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier. Breast J 2020;26(8): 1506–12. DOI:10.1111/tbj.13972; Fong P.C., Boss D.S., Yap T.A. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123–34. DOI:10.1056/NEJMoa0900212; Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007;7(8):573–84. DOI:10.1038/nrc2167; Byrski T., Huzarski T., Dent R. et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009;115(2):359–63. DOI:10.1007/s10549-008-0128-9; Byrski T., Gronwald J., Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28(3):375–9. DOI:10.1200/JCO.2008.20.7019; Silver D.P., Richardson A.L., Eklund A.C. et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(7):1145–53. DOI:10.1200/JCO.2009.22.4725; Loibl S., O’Shaughnessy J., Untch M. et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol 2018;19(4):497–509. DOI:10.1016/S1470-2045(18)30111-6; Zhang J., Yao L., Liu Y. et al. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. Int J Cancer 2021;148(4):941–9. DOI:10.1002/ijc.33234; Mrozek E., Kolesar J., Young D. et al. Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Ann Oncol 2008;19(8):1417–22. DOI:10.1093/annonc/mdn154; Maisano R., Caristi N., Mare M. et al. Mitomycin C plus capecitabine (mixe) in anthracyclineand taxane-pretreated metastatic breast cancer. A multicenter phase II study. Anticancer Res 2007;27(4C):2871–5.; Holánek M., Bílek O., Nenutil R. et al. Effectiveness of neoadjuvant therapy with platinum-based agents for patients with BRCA1 and BRCA2 germline mutations – a retrospective analysis of breast cancer patients treated at MMCI Brno. Klin Onkol 2019;32(Suppl. 2): 31–5. DOI:10.14735/amko2019S31; Banerjee S., Moore K.N., Colombo N. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears. Lancet Oncol 2021;22(12):1721–31. DOI:10.1016/S1470-2045(21)00531-3; Arun B.K., Han H.S., Kaufman B. et al. Efficacy and safety of firstline veliparib and carboplatin-paclitaxel in patients with HER2-advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial. Eur J Cancer 2021;154:35–45. DOI:10.1016/j.ejca.2021.05.037; Diéras V., Han H.S., Kaufman B. et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020;21(10):1269–82. DOI:10.1016/S1470-2045(20)30447-2; Han H.S., Diéras V., Robson M. et al. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol 2018;29(1):154–61. DOI:10.1093/annonc/mdx505; Zhu Y., Wu J., Zhang C. et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7(43):70113–27. DOI:10.18632/oncotarget.12158; Tutt A., Tovey H., Cheang M.C.U. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24(5):628–37. DOI:10.1038/s41591-018-0009-7; Byrski T., Dent R., Blecharz P. et al. Results of a phase II openlabel, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012;14(4):R110. DOI:10.1186/bcr3231; De Vos M., Schreiber V., Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol 2012;84(2):137–46. DOI:10.1016/j.bcp.2012.03.018; Cortesi L., Rugo H.S., Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol 2021;16(3):255–82. DOI:10.1007/s11523-021-00796-4; Robson M.E., Tung N., Conte P. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30(4):558–66. DOI:10.1093/annonc/mdz012; Litton J.K., Rugo H.S., Ettl J. et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753–63. DOI:10.1056/NEJMoa1802905; Ayoub J.P., Wildiers H., Friedlander M. et al. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial. Ther Adv Med Oncol 2021;13:17588359211059601. DOI:10.1177/17588359211059601; Rodler E., Sharma P., Barlow W.E. et al. Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, doubleblind, placebo-controlled, phase 2 trial. Lancet Oncol 2023;24(2):162–74. DOI:10.1016/S1470-2045(22)00739-2; Stefansson O.A., Hilmarsdottir H., Olafsdottir K. et al. BRCA1 promoter methylation status in 1031 primary breast cancers predicts favorable outcomes following chemotherapy. JNCI Cancer Spectr 2019;4(2):pkz100. DOI:10.1093/jncics/pkz100; Kawachi A., Yamashita S., Okochi-Takada E. et al. BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. Breast Cancer Res Treat 2020;181(2):323–9. DOI:10.1007/s10549-020-05647-w; Glodzik D., Bosch A., Hartman J. et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat Commun 2020;11(1):3747. DOI:10.1038/s41467-020-17537-2; Rice J.C., Ozcelik H., Maxeiner P. et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 2000;21(9):1761–5. DOI:10.1093/carcin/21.9.1761; Mo W., Liu Q., Lin C.C. et al. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triplenegative breast cancer. Clin Cancer Res 2016;22(7):1699–712. DOI:10.1158/1078-0432.CCR-15-177; https://umo.abvpress.ru/jour/article/view/564
-
2Academic Journal
المؤلفون: E. A. Busko, V. V. Mortada, P. V. Krivorotko, V. F. Semiglazov, R. S. Pesotsky, А. S. Emelyanov, N. S. Amirov, V. S. Channov, T. T. Tabagua, L. P. Gigolaeva, S. S. Yerechshenko, A. V. Komyakhov, K. S. Nikolaev, K. Y. Zernov, E. K. Zhiltsova, Ya. I. Bondarchuk, D. A. Enaldieva, S. N. Novikov, V. S. Apollonova, A. I. Tseluiko, B. S. Kasparov, Е. А. Бусько, В. В. Мортада, П. В. Криворотько, В. Ф. Семиглазов, Р. С. Песоцкий, А. С. Емельянов, Н. С. Амиров, В. С. Чаннов, Т. Т. Табагуа, Л. П. Гиголаева, С. С. Ерещенко, А. В. Комяхов, К. С. Николаев, К. Ю. Зернов, Е. К. Жильцова, Я. И. Бондарчук, Д. А. Еналдиева, С. Н. Новиков, В. С. Аполлонова, А. И. Целуйко, Б. С. Каспаров
المصدر: Diagnostic radiology and radiotherapy; Том 13, № 3 (2022); 43-50 ; Лучевая диагностика и терапия; Том 13, № 3 (2022); 43-50 ; 2079-5343
مصطلحات موضوعية: новообразования с неопределенным потенциалом злокачественности, vacuum-assisted breast biopsy, ultrasound examination, breast biopsy, breast cancer, вакуум-ассистированная биопсия, ультразвуковое исследование, биопсия молочной железы, рак молочной железы
وصف الملف: application/pdf
Relation: https://radiag.bmoc-spb.ru/jour/article/view/753/559; Lucioni M., Rossi C., Lomoro P. et al. Positive predictive value for malignancy of uncertain malignant potential (B3) breast lesions diagnosed on vacuum-assisted biopsy (VAB): is surgical excision still recommended? // Eur. Radiol. 2021. Vol. 31, No. 2. Р. 920–927. doi:10.1007/s00330-020-07161-5.; Forester N.D., Lowes S., Mitchell E., Twiddy M. High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis // Eur. J. Surg. Oncol. 2019. Vol. 45, No. 4. Р. 519–527. doi:10.1016/j.ejso.2018.12.008.; Andreu F.J., Sáez A., Sentís M. et al. Breast core biopsy reporting categories — аn internal validation in a series of 3054 consecutive lesions // Breast. 2007. Vol. 16, No. 1. Р. 94–101. doi:10.1016/j.breast.2006.06.009.; Eusebi V., Feudale E., Foschini M.P. et al. Long-term follow-up of in situ carcinoma of the breast // Semin. Diagn Pathol. 1994. Vol. 11, No. 3 Р. 223–235.; Perry N., Broeders M., de Wolf C., Törnberg S., Holland R., von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition — summary document // Ann. Oncol. 2008. Vol. 19, No. 4. Р. 614–622. doi:10.1093/annonc/mdm481.; Strachan C., Horgan K., Millican-Slater R.A., Shaaban A.M., Sharma N. Outcome of a new patient pathway for managing B3 breast lesions by vacuum-assisted biopsy: time to change current UK practice? // J. Clin. Pathol. 2016. Vol. 69, No. 3. Р. 248–254. doi:10.1136/jclinpath-2015-203018.; Беляев А.М., Прохоров Г.Г., Криворотько П.В., Бусько Е.А., Захарова В.Д., Петрик С.В., Фролов О.Н. Технология пункционной криоаблации злокачественных опухолей молочной железы // Вопросы онкологии. 2020. Т. 66, № 4. С. 346–352. Belyayev A.M., Prokhorov G.G., Krivorot’ko P.V., Bus’ko Ye.A., Zakharova V.D., Petrik S.V., Frolov O.N. Tekhnologiya punktsionnoy krioablatsii zlokachestvennykh opukholey molochnoy zhelezy // Voprosy onkologii. 2020. T. 66, No. 4. S. 346–352. doi:10.37469/0507-3758-2020-66-4-346-352.; Скурихин С.С., Суворова Ю.В. Вакуумно-аспирационная биопсия в маммологической практике. Анализ 3-летнего опыта применения // Опухоли женской репродуктивной системы. 2020. Т. 16, № 2. С. 19–24. Skurikhin S.S., Suvorova Yu.V. Vakuumno-aspiratsionnaya biopsiya v mammologicheskoy praktike. Analiz 3-letnego opyta primeneniya // Opukholi zhenskoy reproduktivnoy sistemy. 2020. T. 16, No. 2. S. 19–24. doi:10.17650/1994-4098-2020-16-2-19-24.; Image-guided vacuum-assisted excision biopsy of benign breast lesions Interventional procedures guidance National Institute for Health and Clinical Excellence Published: 22 February 2006 www.nice.org.uk/guidance/ipg156.; Pinder S.E., Shaaban A., Deb R. et al. NHS Breast Screening multidisciplinary working group guidelines for the diagnosis and management of breast lesions of uncertain malignant potential on core biopsy (B3 lesions) // Clin. Radiol. 2018. Vol. 73, No. 8. Р. 682–692. doi:10.1016/j.crad.2018.04.004.; Бусько Е.А., Семиглазов В.В., Аполлонова В.С., Целуйко А.И., Смирнова В.О., Шагал М.А., Костромина Е.В., Кадырлеев Р.А., Васильев А.В., Петрик С.В., Денискин О.Н., Козубова К.В., Каспаров Б.С., Артемьева А.С., Заозерский О.В., Шевкунов Л.Н., Гончарова А.Б., Рогачев М.В., Криворотько П.В. Интервенционные технологии в онкомаммологии: учебное пособие для обучающихся в системе высшего и дополнительного профессионального образования. СПб.: ФГБУ «НМИЦ онкологии им. Н.Н.Петрова» Минздрава России, 2020. 81 с. Bus’ko Ye.A., Semiglazov V.V., Apollonova V.S., Tseluyko A.I., Smirnova V.O., Shagal M.A., Kostromina Ye.V., Kadyrleyev R.A., Vasil’yev A.V., Petrik S.V., Deniskin O.N., Kozubova K.V., Kasparov B.S., Artem’yeva A.S., Zaozerskiy O.V., Shevkunov L.N., Goncharova A.B., Rogachev M.V., Krivorot’ko P.V. Interventsionnyye tekhnologii v onkomammologii: uchebnoye posobiye dlya obuchayushchikhsya v sisteme vysshego i dopolnitel’nogo professional’nogo obrazovaniya. St. Petersburg: FGBU «NMITS onkologii im. N.N.Petrova» Minzdrava Rossii, 2020. 81 s.; Акиев Р.М., Атаев А.Г., Багненко С.С., Бойков И.В., Бурлаченко Е.П., Демшина Т.Е., Дударев А.Л., Ищенко Б.И., Лыткина С.И., Малаховский В.Н., Мищенко А.В., Пчелин И.Г., Рамешвили Т.Е., Рудь С.Д., Рязанов В.В., Сигина О.А., Труфанов Г.Е., Трущенко С.Г., Фокин В.А. Лучевая диагностика: учебник. СПб.: ГЭОТАР-Медиа, 2015. 496 с. Akiyev R.M., Atayev A.G., Bagnenko S.S., Boykov I.V., Burlachenko Ye.P., Demshina T.Ye., Dudarev A.L., Ishchenko B.I., Lytkina S.I., Malakhovskiy V.N., Mishchenko A.V., Pchelin I.G., Rameshvili T.Ye., Rud’ S.D., Ryazanov V.V., Sigina O.A., Trufanov G.Ye., Trushchenko S.G., Fokin V.A. Luchevaya diagnostika: uchebnik. St. Petersburg: GEOTAR-Media, 2015. 496 s.; https://radiag.bmoc-spb.ru/jour/article/view/753
-
3Academic Journal
المؤلفون: N. S. Popova, P. I. Krzhivitskiy, S. N. Novikov, V. V. Danilov, A. A. Valitova, Zh. V. Bryantseva, A. V. Chernaya, P. V. Krivorotko, T. T. Tabagua, A. S. Artemyeva, T. S. Yaganova, Н. С. Попова, П. И. Крживицкий, С. Н. Новиков, В. В. Данилов, А. А. Валитова, Ж. В. Брянцева, А. В. Чёрная, П. В. Криворотько, Т. Т. Табагуа, А. С. Артемьева, Т. С. Яганова
المصدر: Medical Visualization; Том 27, № 1 (2023); 35-45 ; Медицинская визуализация; Том 27, № 1 (2023); 35-45 ; 2408-9516 ; 1607-0763
مصطلحات موضوعية: маммосцинтиграфия, molecular breast imaging, mammoscintigraphy, молекулярная визуализация
وصف الملف: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1300/770; Мерабишвили В.М. Злокачественные новообразования в Северо-Западном федеральном округе России / Под ред. проф. Беляева А.М. СПб., 2018: 16–17.; Halperin C.E. Principles and Practice of Radiation oncology. 6th ed. Halperin C.E. et al. Philadelphia: Wolters Kluer-Lippincot Williams&Wilkins, 2013: 568–590.; Ринк П. Магнитный резонанс в медицине / Под ред. проф. Ринка П.: Пер. с англ. Oxford: Blackwell, Scientific Publications, 1995: 4–29. ISNB 5-9231-0320-6; Прокоп М. Спиральная и многослойная компьютерная томография. В 3-х томах. Т. 2. Учебное пособие / Прокоп М., Галански М.: Пер. с англ. Зубарева А.В. и Шотемора Ш.Ш. М.: МЕДепресс-информ, 2006– 2007: 629–631. ISNB 978-5-98322-739-2; Канаев С.В., Новиков С.Н., Зотова О.В., Гиршович М.М., Жукова Л.А., Семиглазов В.Ф., Криворотько П.В., Иванов В.Г. Перспективы использования методов ядерной медицины у больных раком молочной железы. Вопросы онкологии. 2009: 55 (61): 661–670.; Наркевич Б.Я., Костылев В.А. Физические основы ядерной медицины. М.: АМФ-Пресс, 2001: 59.; Крылов А.С., Рыжков А.Д., Ширяев С.В., Гончаров М.О., Крылова М.А., Комановская Д.А., Билик М.Е., Каспшик С.М., Михайлова Е.В., Станякина Е.Е., Жуков Г.А. ОФЭКТ/КТ с 99m Tc-технетрилом в диагностике злокачественных опухолей головы и шеи у детей. Медицинская радиология и радиационная безопасность. 2020; 65 (1): 27–36. http://doi.org/10.12737/1024-6177-2020-65-1-27-36; Чёрная А.В., Канаев С.В., Новиков С.Н., Крживицкий П.И., Криворотько П.В., Жукова Л.А., Бусько Е.А. Диагностическая значимость маммографии и маммосцинтиграфии с 99m Тс-MIBI при выявлении минимального рака молочной железы. Вопросы онкологии. 2017; 63 (2): 274–280.; Goldsmith S.J., Parsons W., Guiberteau M.J. et al. SNM Practice Guideline for Breast Scintigraphy with Breast-Specific g-Cameras 1.0. J. Nucl. Med. Technol. 2010; 38: 219–224. https://doi.org/10.2967/jnmt.110.082271; Тицкая А.А., Чернов В.И., Слонимская Е.М., Синилкин И.Г., Зельчан Р.В. Маммосцинтиграфия с 99m Tс-МИБИ в диагностике рака молочной железы. Сибирский медицинский журнал. 2010; 25 (4): 92–95.; Чёрная А.В., Крживицкий П.И., Бусько Е.А., Криворотько П.В., Артемьева А.С., Попова Н.С., Данилов В.В., Семиглазов В.Ф., Новиков С.Н., Канаев С.В. Роль цифровой маммографии, маммосцинтиграфии с 99m Tc-метоксиизобутилизонитрилом (MIBI) и ультразвукового исследования в диагностике мультицентричного рака молочной железы. Опухоли женской репродуктивной системы. 2019; 15 (4): 12–22.; Величко С.А., Слонимская Е.М., Фролова И.Г., Бухарин Д.Г., Дорошенко А.В. Способ прогнозирования “малых” форм рака молочной железы на фоне фиброзно-кистозной болезни. Бюллетень сибирской медицины. 2017; 16 (1): 13–19.; Sun Y., Wei W., Yang H.W. et al. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: A systemic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging. 2013; 40 (3): 450–463.; Cwikla J.B., Buscombe J.R., Kolasinska A.D. et al. Correlation between uptake of 99m Tc-sestamibi and prognostic faktors of breast cancer. Anticancer Res. 1999; 19: 2299–2304.; Spanu A., Sanna D., Chessa F. et al. The usefulness of Tc-99m-tetrofosmin SPECT/CT in the detection of residual tumors and axillary lymph node metastases in breast cancer patients following neoadjuvant therapy. Clin. Nuclear Med. 2011; 36 (11): 997–1002.; Kim B.S. Usefulness of breast-specic gamma imaging as an adjunct modality in breast cancer patients with dense breast: a comparative study with MRI. Ann. Nucl. Med. 2012; 26: 131–137.; Крживицкий П.И., Новиков С.Н., Канаев С.В., Клиценко О.А., Ильин Н.Д., Попова Н.С., Пономарева О.И., Черная А.В., Труфанова Е.С., Криворотько П.В. ОФЭКТ-КТ в диагностике метастатического поражения лимфатических узлов у больных раком молочной железы. Вопросы онкологии. 2017; 63 (2): 261–273.; Novikov S.N., Krivorotko P.V., Kanaev S.V. et al. Combination of Breast Scintigraphy and Ultrasound is Promising Tool for Diagnosis and Staging of Breast Cancer. Eur. J. Cancer. 2012; 48 (Suppl. 1): 612.; https://medvis.vidar.ru/jour/article/view/1300
-
4Academic Journal
المؤلفون: A. V. Chernaya, R. Kh. Ulyanova, S. S. Bagnenko, P. V. Krivorotko, A. S. Artemyeva, E. K. Zhiltsova, S. N. Novikov, V. V. Danilov, P. I. Krzhivitsky, I. E. Meshkova, A. N. Zaitsev, А. В. Чёрная, Р. Х. Ульянова, С. С Багненко, П. В. Криворотько, А. С. Артемьева, Е. К. Жильцова, С. Н. Новиков, В. В. Данилов, П. И. Крживицкий, И. Е. Мешкова, А. Н. Зайцев
المصدر: Medical Visualization; Том 27, № 1 (2023); 25-34 ; Медицинская визуализация; Том 27, № 1 (2023); 25-34 ; 2408-9516 ; 1607-0763
مصطلحات موضوعية: доброкачественные образования молочной железы, contrast enhanced spectral mammography, digital mammography, dense breast tissue, benign breast tumors, контрастная спектральная двухэнергетическая маммография, цифровая маммография, повышенная плотность тканей молочных желез
وصف الملف: application/pdf
Relation: https://medvis.vidar.ru/jour/article/view/1314/784; Sprague B.L., Gangnon R.E., Burt V. et al. Prevalence of mammographically dense breasts in the United States. J. Natl. Cancer Inst. 2014; 106 (10): dju255. http://doi.org/10.1093/jnci/dju255; Kolb T.M., Lichy J., Newhouse J.H. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002; 225 (1): 165–175. http://doi.org/10.1148/radiol.2251011667; Bertrand K.A., Tamimi R.M., Scott C.G. et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013; 15 (6): R104. http://doi.org/10.1186/bcr3570; Sartor H., Zackrisson S., Elebro K. et al. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer. Cancer Causes Control. 2015; 26 (6): 931–939. http://doi.org/10.1007/s10552-015-0576-6; Sung H., Ren J., Li J. et al. Breast cancer risk factors and mammographic density among high-risk women in urban China. NPJ Breast Cancer. 2018; 4 (1): 3. http://doi.org/10.1038/s41523-018-0055-9; Huppe A.I., Mehta A.K., Brem R.F. Molecular breast imaging: a comprehensive review. Semin Ultrasound CT MR. 2018; 39 (1): 60–69. http://doi.org/10.1053/j.sult.2017.10.001; Чёрная А.В., Канаев С.В., Новиков С.Н., Крживицкий П.И., Криворотько П.В., Жукова Л., Бусько Е.А. Диагностическая значимость маммографии и маммосцинтиграфии с 99m Тс-MIBI при выявлении минимального рака молочной железы. Вопросы онкологии. 2017; 63 (2): 274–280. https://doi.org/10.37469/0507-3758-2017-63-2-274-280; Adrada B.E., Candelaria R., Rauch G.M. MRI for the Staging and Evaluation of Response to Therapy in Breast Cancer. Top Magn. Reson. Imaging. 2017; 26 (5): 211–218. https://doi.org/10.1097/RMR.0000000000000147; Семиглазов В.Ф., Комяхов А.В., Семиглазов В.В., Дашян Г.А., Петренко О.Л., Петрова А.С. Магнитно-резонансная томография в первичной диагностике и оценке эффективности неоадъювантной терапии у больных раком молочной железы. Эффективная фармакотерапия. 2015; 10: 44–53.; Чёрная А.В., Новиков С.Н., Криворотько П.В., Ульянова Р.Х., Данилов В.В. Новые технологии при выявлении рака молочной железы – контрастная двухэнергетическая спектральная маммография. Медицинская визуализация. 2019; 2: 49–61. https://doi.org/10.24835/1607-0763-2019-2-49-61; Patel B.K., Naylor M.E., Kosiorek H.E. et al. Clinical utility of contrast-enhanced spectral mammography as an adjunct for tomosynthesis-detected architectural distortion. Clin. Imaging. 2017; 46: 44–52. https://doi.org/10.1016/j.clinimag.2017.07.003; Чёрная А.В., Ульянова Р.Х., Криворотько П.В., Артемьева А.С., Багненко С.С., Жильцова Е.К., Новиков С.Н., Данилов В.В., Крживицкий П.И., Семиглазов В.Ф. Возможности контрастной спектральной двухэнергетической маммографии в диагностике мультицентричного рака молочной железы. Опухоли женской репро дуктивной системы. 2021; 17 (4): 20–28. https://doi.org/10.17650/1994-4098-2021-17-4-20-28; Чёрная А.В, Бусько Е.А., Канаев С.Н., Новиков С.Н., Криворотько П.В., Крживицкий П.И., Попова Н.С., Артемьева А.С., Шумакова Т.А. Маммография и маммосцинтиграфия с 99m Тс-MIBI в диагностике мультицентричного рака молочной железы. Вопросы онкологии. 2017; 63 (6): 876–881.; Чёрная А.В., Крживицкий П.И., Бусько Е.А., Криворотько П.В., Артемьева А.С., Попова Н.С., Данилов В.В., Семиглазов В.Ф., Новиков С.Н., Канаев С.В. Роль цифровой маммографии, маммосцинтиграфии с 99m-метоксиизобутилизонитрилом (MIBI) и ультразвукового исследования в диагностике мультицентричного рака молочной железы. Опухоли женской репродуктивной системы. 2019; 15 (4): 12–22. https://doi.org/10.17650/1994-4098-2019-15-4-12-22; https://medvis.vidar.ru/jour/article/view/1314
-
5Academic Journal
المؤلفون: V. F. Semiglazov, V. V. Semiglazov, G. A. Dashyan, P. V. Krivorotko, V. G. Ivanov, E. K. Zhiltsova, R. M. Paltuev, L. M. Bershtein, T. Yu. Semiglazova, S. S. Yerechshenko, V. V. Klimenko, V. S. Apollonova, A. V. Komyahov, A. A. Bessonov, В. Ф. Семиглазов, В. В. Семиглазов, Г. А. Дашян, П. В. Криворотько, В. Г. Иванов, Е. К. Жильцова, Р. М. Палтуев, Л. М. Берштейн, Т. Ю. Семиглазова, С. С. Ерещенко, В. В. Клименко, В. С. Аполлонова, А. В. Комяхов, А. А. Бессонов
المصدر: Siberian journal of oncology; Том 17, № 3 (2018); 11-19 ; Сибирский онкологический журнал; Том 17, № 3 (2018); 11-19 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2018-17-3
مصطلحات موضوعية: гормонзависимые опухоли, neoadjuvant endocrine therapy, ER+ breast cancer, hormone-dependent tumors, неоадъювантная эндокринотерапия, эстроген-рецептор-положительные опухоли
وصف الملف: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/758/532; Семиглазов В.Ф., Криворотько П.В., Семиглазова Т.Ю., Николаев К.С., Комяхов А.В., Дашян Г.А., Семиглазов В.В., Палутев Р.М. Рекомендации по лечению рака молочной железы. М.: Мегаполис, 2017. 168; Goldhirsch A., Winer E.P., Coates A.S., Gelber R.D., Piccart-Gebhart M., Thürlimann B., Senn H.J.; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013 Sep; 24 (9): 2206–23. doi:10.1093/annonc/mdt303.; Eiermann W., Paepke S., Appfelstaedt J., Llombart-Cussac A., Eremin J., Vinholes J., Mauriac L., Ellis M., Lassus M., Chaudri-Ross H.A., Dugan M., Borgs M.; Letrozole Neo- Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001 Nov; 12 (11): 1527–32.; Ellis M.J., Coop A., Singh B., Mauriac L., Llombert-Cussac A., Jänicke F., Miller W.R., Evans D.B., Dugan M., Brady C., Quebe- Fehling E., Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001 Sep 15; 19 (18): 3808–16. doi:10.1200/JCO.2001.19.18.3808.; Smith I.E., Dowsett M. Comparison of anastozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptorpositive (ER+) operable breast cancer in postmenopausal women: the IMPACT trial. Breast Cancer. Res. 2003; 82: S6.; Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Ziltsova E.K., Ivanov V.G., Bozhok A.A., Berstein L.M. Phase II randomized trial of primary endocrine therapy chemotherapy in postmenopausal patients with estrogen receptor positive breast cancer. Cancer. 2007, 110 (2): 244–254.; Semiglazov V.F., Dashyan G.A., Semiglazov V.V., Petrenko O.L., Komyahov A.V., Paltuev R.M., Matzko D. P198 Prognostic values of breast cancer subtypes : from phase 2 randomized trial of neoadjuvant therapy. The Breast, 2015; 24: S92.; Cardoso F., Costa A., Norton L., Senkus E., Aapro M., Andre F., Cardoso M.J. ESO-ESMO 2nd international consensus guidelines for advanced breast Cancer (ABC2). Simultaneous And Annals of Oncology. 2014: 25: 1871–1888.; Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., Ettl J., Patel R., Pinter T., Schmidt M., Shparyk Y., Thummala A.R., Voytko N.L., Fowst C., Huang X., Kim S.T., Randolph S., Slamon D.J. The cyclin – dependent kinase 4/6 inhibitor palbociclib on combination with letrozole versus letrozole alone as first-line treatment of estrogen receptorpositive, HER2- negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomized phase 2 study. Lancet Oncol. 2015 Jan; 16 (1): 25–35. doi:10.1016/S1470-2045(14)71159-3.; Turner N.C., Huang Bartlett C., Cristofanilli M. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Oct 22; 373 (17): 1672–3. doi:10.1056/NEJMc1510345.; Finn R.S., Martin M., Rugo H.S., Jones S.E., Im S.A., Gelmon K.A., Gauthier E.R. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ERb/HER2e advanced breast cancer (ABC). J Clin Oncol 2016; 34. Abstr 507.; Weigel R.J., de Coninck E.C. Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma. Cancer Res. 1993 Aug 1; 53 (15): 3472–4.; Fribbens C., O’Leary B., Kilburn L., Hrebien S., Garcia-Murillas I., Beaney M., Cristofanilli M., Andre F., Loi S., Loibl S., Jiang J., Bartlett C.H., Koehler M., Dowsett M., Bliss J.M., Johnston S.R., Turner N.C. Plasma ESR1 mutations and the treatment of estrogen receptor- positive advanced breast cancer. J Clin Oncol. 2016 Sep 1; 34 (25): 2961–8. doi:10.1200/JCO.2016.67.3061; Harbeck N., Iyer S., Turner N., Cristofanilli M., Ro J., André F., Loi S., Verma S., Iwata H., Bhattacharyya H., Puyana Theall K., Bartlett C.H., Loibl S. Quality of life with palbociclib plus full-vestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016 Jun; 27 (6): 1047–54. doi:10.1093/annonc/mdw139.; Bachelot T., Bourgier C., Cropet C., Ray-Coquard I., Ferrero J.M., Freyer G., Abadie- Lacourtoisie S., Eymard J.C., Debled M., Spaëth D., Legouffe E., Allouache D., El Kouri C., Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2- negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1; 30 (22): 2718–24. doi:10.1200/JCO.2011.39.0708.; https://www.siboncoj.ru/jour/article/view/758
-
6Academic Journal
المؤلفون: V. F. Semiglazov, A. I. Tseluiko, R. V. Donskikh, P. V. Krivorotko, G. A. Dashyan, V. V. Semiglazov, A. V. Komyakhov, В. Ф. Семиглазов, А. И. Целуйко, Р. В. Донских, П. В. Криворотько, Г. А. Дашян, В. В. Семиглазов, А. В. Комяхов
المصدر: Meditsinskiy sovet = Medical Council; № 19 (2018); 12-16 ; Медицинский Совет; № 19 (2018); 12-16 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-19
مصطلحات موضوعية: иммунотерапия, immuno-oncology, immunotherapy, иммуноонкология
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2740/2692; Denkert C, Loibl S, Noske A, et al. Tumorassociated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol, 2010, 28: 105-113.; Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol, 2015, 33: 983–91.; Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med, 2016, 13: e1002194.; Berke G, The binding and cellular aspects. Ann Rev Immunol, 1994, 12: 735-773.; Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol, 2011, 8: 151-160.; Zitvogel L, Galluzzi L, Kepp O, SmythMJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol, 2015, 15(7): 405-414.; Segal NH, Parsons DW, Peggs KS, et al. Epitope landscape in breast and colorectal cancer. Cancer Res, 2008, 68: 889-892.; Semiglazov VF. Dependence of clinical course in breast cancer on pathology. Radiobiol Radiother, 1974, 3: 361-364.; Семиглазов В.Ф., Криворотько П.В., Семиглазов В.В., Дашян Г.А., Палтуев Р.М. Рекомендации для врачей по ведению пациентов с раком молочной железы. М.: Ремедиум, 2017. 240 с.; Хаитов Р.М., Кадаидзе З.Г. Иммунитет и рак. М.: ГЭОТАР-Медиа, 2018, 251 с.; Петров Р.В., Хаитов Р.М. Иммунология и вакцины нового поколения. М.: ГЭОТАРМедиа, 2011, 608 с.; Семиглазов В.Ф., Семиглазов В.В. Лечение рака молочной железы. Клиникобиологическое обоснование. М.: СИМК, 2017. 227 с.; Кадагидзе З.Г., Черткова А.И., Славина Е.Г. Регуляторные Т-клетки и их роль в противоопухолевом иммунном ответе. Вопросы онкологии, 2009, 55(3): 269-277.; Колядина И.В., Поддубная И.В., Van de Velde и соавт. Иммунная гетерогенность рака молочной железы I стадии: биологическое, популяционное и прогностическое значение. Современная онкология, 2015, 17(1): 30-38.; Emens L, Adams S, Loi S. et al. A phase III randomized trial of atezolizumab in combination with nab. paclitaxel as first line therapy for patients with metastatic triple – negative breast cancer (mTNBC). San-Antonio Breast Cancer Simposium. 2015. OT1-01-06.; Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Presented at San Antonio Breast Cancer Symposium. December 9-13, 2014. San Antonio, TX.; Adams S, Diamond JR, Hamilton EP et al. Phase IB trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol, 2016, 34(Suppl. 15): 1009-1009.; Perdoza-Gonzalez A, Xu K, Wu TC, et al. Thymic stromal lemphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med, 2011, 208: 479-490.; Cecil DL, Holt GE, Park KH, et al. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity. Cancer Res, 2014, 74: 2710-2718.; Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med, 2005, 353(25): 2654-2666.; HwangWT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumorinfiltrating T cells in ovarian cancer: ametaanalysis. Gynecol Oncol, 2012, 124(2): 192-198.; Dieu-Nosjean MC, Antoine M, Danel C, et al. Long-term survival for patients with nonsmall-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol, 2008, 26(27): 4410-4417.; Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer, 2012, 12(4): 298-306.; Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol, 2007, 19(2): 209-216.; Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer, 2006, 94: 259-267; https://www.med-sovet.pro/jour/article/view/2740
-
7Academic Journal
المؤلفون: Л. П. Гиголаева, А. А. Бессонов, П. В. Криворотько, Г. А. Дашян, Ш. М. Хаджиматова, E. К. Жильцова, А. В. Комяхов, Т. Т. Табагуа, С. С. Ерещенко, А. С. Емельянов, Р. С. Песоцкий, К. С. Николаев, E. С. Труфанова, А. П. Соколенко, E. H. Имянитов, В. Ф. Семиглазов
المصدر: Malignant tumours; Том 8, № 3s1 (2018); 29-36 ; Злокачественные опухоли; Том 8, № 3s1 (2018); 29-36 ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: наследственные синдромы, трижды негативный рак молочной железы
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/542/378; Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108:171–182. http://www.ncbi.nlm.nih.gov/pubmed/11832208.; D’Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003; 3:23–34. doi:10.1038/nrc970.3. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. The Breast. 2010; 19:312–321. doi:10.1016/j.breast.2010.03.026.; Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res. 2010; 12:S3. doi:10.1186/bcr2574.; Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003; 95:1482–1485. http://www.ncbi.nlm.nih.gov/pubmed/14519755.; Atchley DP, Albarracin CT, Lopez A, et al. Clinical and Pathologic Characteristics of Patients With BRCA -Positive and BRCA –Negative Breast Cancer. J Clin Oncol. 2008; 26:4282–4288. doi:10.1200/JCO.2008.16.6231.; Couch FJ, Hart SN, Sharma P, et al. Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. J Clin Oncol. 2015; 33:304–311. doi:10.1200/JCO.2014.57.1414.; Engel C, Rhiem K, Hahnen E, et al. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triplenegative breast cancer without family cancer history. BMC Cancer. 2018; 18:265. doi:10.1186/s12885-018-4029-y.; Turner N, Lambros MB, Horlings HM, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010; 29:2013–2023. doi:10.1038/onc.2009.489.; Sharma P, Stecklein SR, Kimler BF, et al. The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer. J cancer Ther Res. 2014; 3:111. doi:10.7243/2049-7962-3-2.; Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014; 232:142–150. doi:10.1002/path.4280.3; Masuda H, Baggerly KA, Wang Y, et al. Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes. Clin Cancer Res. 2013; 19:5533–5540. doi:10.1158/1078-0432.CCR-13-0799.; Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100:8418–8423. doi:10.1073/pnas.0932692100.; Copson ER, Maishman TC, Tapper WJ, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018; 19:169–180. doi:10.1016/S1470-2045(17)30891-4.; Jiang T, Shi W, Wali VB, et al. Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. Ladanyi M, ed. PLOS Med. 2016; 13:e1002193. doi:10.1371/journal.pmed.1002193.; Bayraktar S., Gluck S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Research and Treatment. 2012. Vol. 135(2). – P. 355–366.; Kriege M. et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of Clinical Oncology. 2009. Vol. 27(23). P. 3764–3771.; Treszezamsky A.D. et al. BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Research. 2007. Vol. 67(15). P. 7078–7081.; Quinn J.E. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Research. 2003. Vol. 63(19). P. 6221–6228.; Miyoshi Y. et al. Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicinbased regimens for human breast cancers. Cancer Letters. 2008. Vol. 264(1). P. 44–53.; Liedtke C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology. 2008. Vol. 26(8). P. 1275–1281.; Carey L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clinical Cancer Research. 2007. Vol. 13 (8). P. 2329–2334.; Chappuis P.O. et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. Journal of Medical Genetics. 2002. Vol. 39(8). P. 608–610.; Rouzier R. et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clinical Cancer Research. 2005. Vol. 11 (16). P. 5678–5685.; Hubert A. et al. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Familial Cancer. 2009. Vol. 8(3). P. 173–177.; https://www.malignanttumors.org/jour/article/view/542; undefined
-
8Academic Journal
المؤلفون: M. A. Osipov, T. U. Semiglazova, P. V. Krivorotko, V. V. Klimenko, V. A. Kostorov, V. V. Semiglazov, E. V. Tsyrlina, I. G. Popovich, V. N. Anisimov, V. F. Semiglazov, L. M. Berstein, М. А. Осипов, Т. Ю. Семиглазова, П. В. Криворотько, В. В. Клименко, В. А. Косторов, В. В. Семиглазов, Е. В. Цырлина, И. Г. Попович, В. Н. Анисимов, В. Ф. Семиглазов, Л. М. Берштейн
المصدر: Malignant tumours; № 2 (2017); 76-82 ; Злокачественные опухоли; № 2 (2017); 76-82 ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: клинические исследования, metformin, chemotherapy, hormonal therapy, clinical trials, метформин, химиотерапия, гормонотерапия
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/346/313; Berstein L.M. Antidiabetic biguanide metformin and cancer incidence, Diabetes mellitus, 2010, Vol. 3, pp. 45–48.; Berstein L.M., Vasilyev D. A., Iyevleva A.G. et al. Potential and real ‘antineoplastic’ and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females, Future Oncol., 2015, Vol. 11, No. 5, pp. 759–70.; Dilman V.M., Sofronov V.N., Anisimov V.N. et al. elimination of phenformin immunosuppression caused by 1,2 – dimethylhydrazine in rats, Probl. in Onc., 1977, Vol. 23, No. 8, pp. 50–54.; Dilman V.M., Anisimov V.N., Effect of treatment with phenformin, diphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice, Gerontology, 1980, Vol. 26, pp. 241–246.; Dilman V.M., Berstein L.M., Yevtushenko T. P. et al. Preliminary evidence on metabolic rehabilitation in cancer patients, Arch. Geschwulstforsch., 1988, Vol. 58, pp. 175–183.; Dilman V.M., Berstein L.M., Zabezhinski M. A. et al. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats, Arch. Geschwulstforsch, 1978, Vol. 48, pp. 1–8.; Anisimov V.N. Influence of Buformin and diphenin on life span, estrous function and frequency of spontaneous tumors in female rats, Probl. in Onc., 1980, Vol. 26, No. 6.; Anisimov V.N., Alexandrov V.A., Belous N.M., Vasileva I.A. Buformin inhibit transplacental blastomogenic effect of nitrosomethylurea in rrats, Bull. of Exp. Biol. and Med., 1980, Vol 89, No. 7, pp. 88–90.; Anisimov V.N., Belous N.M., Vasileva I. A., Dilman V.M. Phenformin inhibits of mammary tumor development induced by of N – nitrosomethylurea in rats, Exp. Onc., 1980, Vol. 2, No. 3, pp. 40–43.; Alexandrov V., Anisimov V., Belous N. et al. The inhibition of the transplacental blastomogenic effect of nitrosomethylurea by postnatal administration of buformin to rats, Carcinogenesis, 1980, Vol. 1, pp. 975–978.; Anisimov V.N. Do metformin a real anticarcinogen? A critical reapraisal of experimental data, Ann. Transl. Med., 2014, Vol. 2, No. 6, p. 60. doi:10.3978/j. issn. 2305-5839.2014.06.02.; Anisimov V.N. Metfomin for cancer and aging prevention: is it a time to make the long story short? Oncotarget, 2015, Vol. 6, No. 37, pp. 39398–39407. doi:10.18632/oncotarget. 6347.; Chan A. T. Metformin for cancer prevention: a reason for optimism, Lancet Oncol., 2016, Vol. 17, No. 4., pp. 407–409. doi:10.1016/S1470–2045 (16) 00006-1.; Bolin L., Zeying F., Susan M. et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells, Cell Cycle, 2009, Vol. 8, pp. 2031–2040.; Cheong J. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin. Is effective against a broad spectrum of preclinical cancer models, Mol. Cancer Therap., 2011, Vol. 10, No. 12, pp. 2350–2362.; Phoenix K., Vumbaca F., Claffey K. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model, Breast Cancer Res. Treat., 2008, Vol. 113, pp. 101–111.; Ilipoulos D., Hirsch H. A., Struhl K. Metformin decreases the doses of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types, Cancer Res., 2011, Vol. 71, pp. 3196–3201.; Hirsch H., Iliopoulos D., Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth, Proc. Natl. Acad. Sci. USA., 2013, Vol. 110, pp. 972–977.; Osipov M. A., Semiglazova T.U., Popovich I. G. Efficacy of paclitaxel, metformin, melatonin and their combinations in on the growth of transplantable HER–2 positive breeat tumor in female FVB/N mice, J. Malignant Tumors, 2016, Vol. 4(s), p. 324.; Wang Y., Wei J., Li L. et al. Combined use of metformin and everolimus is synergistic in the treatment of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.; Zhuang Y., Miskimins W. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1, J. Mol. Signal, 2008, Vol. 3, pp. 18.; Lau Y., Du X., Rayannavar V. Metformin and erlotinib synergize to inhibit basal breast cancer, Oncotarget, 2014, Vol. 5, No. 21, pp. 10503–17.; Berstein L., Yue W., Wang J., Santen R. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifenresistant, and estrogen-deprived MCF-7 cells, Breast Cancer Res. Treat., 2011, Vol. 128, No. 1, pp. 109–17.; Ashour A., Sayed-Ahmed M., Abd-Allah A. et al. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats, Oxid. Med. Cel. Longev., 2012, Vol. 17:34195.; Soo J., Ng C., Tan S. et al. Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells, Apoptosis, 2015, Vol. 20, No. 10, pp. 1373–87.; Zhou G., Myers R., Li Y. et al. Role of AMPactivated protein kinase in mechanism of metformin action, J. Clin. Invest., 2001, Vol. 108, No 8, pp. 1167–1174.; Xianbin C., Xi H., Xiaojun T. et al. Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo, PLoS One, 2015, Vol. 10, No. 7: e0133349.; Shackelford D., Shaw R. The LKB1-AMPK pathway: metabolism and growth control in tumour suppression, Nat. Rev. Cancer, 2009, Vol. 9, No. 8, pp. 563–575.; Mei P., Kwame O., Darko Т. et al. Combination of Metformin with Chemotherapeutic Drugs via Different Molecular Mechanisms, Cancer Treatment Reviews, 2017. doi:10.1016/j.ctrv.2017.01.005.; Jia Y., Ma Z., Liu X. et al. Metformin prevents DMH-induced colorectal cancer in diabetic rats by reversing the warburg effect of breast cancer cells, Oncol. Res., 2015, Vol. 22, No. 4, pp. 193–201.; Pierotti M. A., Berrino F., Gariboldi M. et al. Targeting metabolism for cancer treatment and prevention: Metformin, an old drug with multi-faceted effects, Oncogene, 2013, Vol. 32, No. 12, pp. 1475–1487.; Pollak M. Metformin and other biguanides in oncology: advancing the research agenda, Cancer Prev. Res. (Phila), 2010, Vol. 3, Nol. 9, pp. 1060–1065.; Brown K., Hunger N., Docanto M. Simpson E. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase, Breast Cancer Res. Treat., 2010, Vol. 123, pp. 591–596.; Vazquez-Martin A., Oliveras-Ferraros C. Menendez J. A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells, Cell Cycle, 2009, Vol. 8, pp. 88–96.; Evans J.M., Donnelly L. A., Emslie-Smith A.M. et al. Metformin and reduced risk of cancer in diabetic patients, BMJ, 2005, Vol. 330, pp. 1304–5.; Landman G., Kleefstra N., van Hateren G. Metformin associated with lower cancer mortality in type-2 diabetes: ZODIAC – 16, Diabetes care, 2010, Vol. 33, No. 2, pp. 322–326.; Bosco J., Antonsen S., S rensen H. Metformin and incident breast cancer among diabetic women: a population-based casecontrol study in Denmark, Cancer Epidemiol. Biomarkers Prev., 2011, Vol. 20, No. 1, pp. 101–11.; Libby G., Donnely L., Donnan P. et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes, Diabetes Care, 2009, Vol. 32, pp. 1620–1625.; Bodmer M., Meier C., Krahenbuhl S. et al. Long-term metformin use is associated with decreased risk of breast cancer, Diabetes Care, 2010, Vol. 33, pp. 1304–8.; Lega I., Austin P., Gruneir A. et al. Association between metformin therapy and mortality after breast cancer: a population-based study, Diabetes Care, 2013, Vol. 36, pp. 3018–3026.; Oppong B., Pharmer L., Oskar S. et al. The effect of metformin on breast cancer outcomes in patients with type 2 diabetes, Cancer Med., 2014, Vol. 3, pp. 1025–1034.; Bayraktar S., Hernadez-Aya L., Lei X. et al. Effect of metformin on survival outcomes in diabetic patients with triple receptornegative breast cancer, Cancer, 2012, Vol. 118, pp. 1202–1211.; Peeters P., Bazelier M., Vestergaard P. et al. Use of metformin and survival of diabetic women with breast cancer, Curr. Drug Saf., 2013, Vol. 8, pp. 357–63.; He X., Esteva F., Ensor J. et al. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer, Ann. Oncol., 2012, Vol. 23, pp. 1771–80.; Kim H., Kwon H., Lee J. Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes, Breast Cancer Res., 2015, Vol. 17, p. 64.; Семиглазова Т. Ю., Клименко В. В., Филатова Л. В. и др. Маркеры эффективности предоперационной таксансодержащей химиотерапии местнораспространенного рака молочной железы // Вопр. онкологии. 2013. Т. 59. № 3. С. 363–368.; [Semiglazova T. J., Klimenko V. V., Filatova L.V. i dr. Markery effektivnosti predoperatsionnoy taksansoderzhashchey khimioterapii mestnorasprostranennogo raka molochnoy zhelezy, Vopr. onkologii, 2013, Vol. 59, No. 3, pp. 363–368. (In Russ.)].; Sao J., Shana L., Sharon H. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer, J. Clin. Onc., 2009, Vol. 27, pp. 3297–3302.; Van Der Laat A. Neoadjuvant metformin along with systemic therapy increase pathological complete responses in breast cancer: Results of a cross-sectional study, Hospital Mexico, Costa Rica, J. Clin. Oncol., 2016, Vol. 34, e12519.; Niraula S., Dowling R., Ennis M. et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study, Breast Cancer Res. Treat., 2012, Vol. 135, No. 3, pp. 821–30.; Bonanni B., Puntoni M., Cazzaniga M. et al. Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial, J. Clin. Oncol., 2012, Vol. 30, No. 21, pp. 2593–600.; Hadad S., Iwamoto T., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial, Breast Cancer Res. Treat., 2011, Vol. 128, No. 3, pp. 783–94.; Hadad S., Coates. P., Jordan L. et al. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial, Breast Cancer Res. Treat., 2015, Vol. 150, No. 1, pp. 149–55.; Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506777.; Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer, ClinicalTrials.gov, Identifier: NCT02506790.; https://www.malignanttumors.org/jour/article/view/346
-
9Academic Journal
المؤلفون: E. K. ZILTSOVA, O. A. IVANOVA, P. V. KRIVOROTKO, V. G. IVANOV, E. V. CYRLINA, G. A. DASHYAN, T. T. TABAGUA, K. S. NIKOLAEV, L. P. GIGOLAEVA, V. F. SEMIGLAZOV, Е. К. ЖИЛЬЦОВА, О. А. ИВАНОВА, П. В. КРИВОРОТЬКО, В. Г. ИВАНОВ, Е. В. ЦЫРЛИНА, Г. А. ДАШЯН, Т. Т. ТАБАГУА, К. С. НИКОЛАЕВ, Л. П. ГИГОЛАЕВА, В. Ф. СЕМИГЛАЗОВ
المصدر: Malignant tumours; № 1 (2017); 18-25 ; Злокачественные опухоли; № 1 (2017); 18-25 ; 2587-6813 ; 2224-5057
مصطلحات موضوعية: рецептор андрогена, triple negative breast cancer, androgen receptor, трижды негативный рак молочной железы
وصف الملف: application/pdf
Relation: https://www.malignanttumors.org/jour/article/view/322/276; DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64:52–62.; Curtis C., Shah S. P., Chin S. F., Turashvili G., Rueda O. M., Dunning M. J. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486:346–52.; Santagata S., Thakkar A., Ergonul A., Wang B., Woo T., Hu R. et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest 2014; 124:859–70.; Perou C. M., Sorlie T., Eisen M. B., van de Rijn M., Jeffrey S. S., Rees C. A. et al. Molecular portraits of human breast tumours. Nature 2000; 406:747–52.; de Ruijter T. C., Veeck J., de Hoon J. P., van Engeland M., Tjan-Heijnen V. C. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137:183–92.; Bosch A., Eroles P., Zaragoza R., Vina J. R., Lluch A. Triplenegative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev 2010; 36:206–15.; Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429–34.; Metzger-Filho O., Tutt A., de Azambuja E., Saini K. S., Viale G., Loi S. et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012; 30:1879–87.; Jiao Q., Wu A., Shao G., Peng H., Wang M., Ji S. et al. The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers. J Thorac Dis 2014; 6:1329–35.; McNamara K.M., Yoda T., Takagi K., Miki Y., Suzuki T., Sasano H. Androgen receptor in triple negative breast cancer. J Steroid Biochem Mol Biol 2013; 133:66–76.; McNamara K.M., Moore N. L., Hickey T. E., Sasano H., Tilley W. D. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer 2014; 21: T161–81.; Safarpour D., Pakneshan S., Tavassoli F. A. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res 2014; 4:353–68.; Crown J., O’Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012; 23(Suppl 6): vi56–65.; Gao, W. Androgen receptor as a therapeutic target. Adv. Drug.Deliv. Rev. 2010 Oct. – Vol. 62, N13. – P. 1277–1284.; Hu Z., Fan C., Oh D. S. et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7:96.; Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490:61–70.; Lehmann B. D., Bauer J. A., Chen X., Sanders M. E., Chakravarthy A. B., Shyr Y. et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750–67.; Xu H., Eirew P., Mullaly S. C., Aparicio S. The omics of triplenegative breast cancers. Clin Chem 2014; 60:122–33.; Perou C. M. Molecular stratification of triple-negative breast cancers. Oncologist 2010; 15(Suppl 5):39–48.; Park H. S., Jang M. H., Kim E. J., Kim H. J., Lee H. J., Kim Y. J. et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol 2014; 27:1212–22.; Baselga J., Gomez P., Greil R., Braga S., Climent M. A.,Wardley A. M. et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol 2013; 31:2586–92.; Shah S. P., Roth A., Goya R., Oloumi A., Ha G., Zhao Y. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486:395–9.; Banerji S., Cibulskis K., Rangel-Escareno C., Brown K. K., Carter S. L., Frederick A. M. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405–9.; Barbie T. U., Alexe G., Aref A. R., Li S., Zhu Z., Zhang X. et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest 2014; 124:5411–23.; Gucalp A., Tolaney S., Isakoff S. J., Ingle J. N., Liu M. C., Carey L. A. et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res 2013; 19:5505–12.; Paul A., Gunewardena S., Stecklein S. R., Saha B., Parelkar N., Danley M. et al. PKClambda/iota signaling promotes triplenegative breast cancer growth and metastasis. Cell Death Differ 2014; 21:1469–81.; Androgen receptor expression and breast cancer survival in postmenopausal women / R. Hu et al. // Clin. Cancer. Res. – 2011 Apr. – Vol. 17, N7. – P. 1867–1874.; Tsang J. Y., Ni Y. B., Chan S. K., Shao M. M., Law B. K., Tan P. H. et al. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers. Ann Surg Oncol 2014; 21:2218–28.; Lim E., Ni M., Cao S., Hazra A., Tamimi R. M., Brown M. Importance of breast cancer subtype in the development of androgen receptor directed therapy. Curr Breast Cancer Rep 2014; 6:71–8.; Hickey T. E., Robinson J. L., Carroll J. S., Tilley W. D. Minireview: the androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene? Mol Endocrinol 2012; 26:1252–67.; Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype / L. J. McGhan et al. // Ann. Surg. Oncol. – 2014 Feb. – Vol. 21, N2. – P. 361–367.; Prognostic markers in triple-negative breast cancer / E. A. Rakha et al. // Cancer. – 2007 Jan. – Vol. 109, N1. – P. 25–32.; Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray / J. He et al. //Med. Oncol. – 2012 Jun. – Vol. 29, N2. – P. 406–410.; Expression of androgen receptors in primary breast cancer / S. Park et al. // Ann. Oncol. – 2010 Mar. – Vol.21, N3. – P. 488– 492.; Cuenca-Lopez M.D., Montero J. C., Morales J. C., Prat A., Pandiella A., Ocana A. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer 2014; 14:302.; Lehmann B. D., Bauer J. A., Schafer J. M., Pendleton C. S., Tang L., Johnson K. C. et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res 2014; 16:406.; Cochrane D. R., Bernales S., Jacobsen B. M., Cittelly D. M., Howe E. N., D’Amato N.C. et al. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res 2014; 16: R7.; Stage 1 results from MDV3100–11: a 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor. In: Advanced AR+ triple-negative breast cancer (TNBC) 37th annual San Antonio breast cancer symposium, 2014.; Kwok C. W., Treeck O., Buchholz S., Seitz S., Ortmann O., Engel J. B. Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC). Target Oncol 2014.; Rizza P., Barone I., Zito D., Giordano F., Lanzino M., De Amicis F. et al. Estrogen receptor beta as a novel target of androgen receptor action in breast cancer cell lines. Breast Cancer Res 2014; 16: R21.; https://www.malignanttumors.org/jour/article/view/322
-
10
المؤلفون: Е. А. Бусько, В. В. Семиглазов, А. В. Мищенко, К. В. Козубова, А. С. Шишова, М. И. Арабачян, Е. В. Костромина, П. В. Криворотько, E. A. Busko, V. V. Semiglazov, A. V. Mishchenko, K. V. Kozubova, A. S. Shishova, M. I. Arabachyan, E. V. Kostromina, P. V. Krivorotko
المصدر: Diagnostic radiology and radiotherapy ; Лучевая диагностика и терапия
مصطلحات موضوعية: cancer, benign breast lesions, ultrasound (US), sonoelastography (SEG), Color Doppler Mapping (CDM), BI-RADS system, histological evaluation, рак молочной железы, доброкачественные образования молочной железы, ультразвуковое исследование (УЗИ), соноэластография (СЭГ), цветовое допплеровское картирование (ЦДК), система BI-RADS, гистологическое заключение